The short-term safety of adjuvant paclitaxel plus trastuzumab - A single centre experience

ATEŞ Ö., Sunar V., Aslan A., Karatas F., Sahin S., Altundag K.

JOURNAL OF BUON, vol.22, no.2, pp.320-324, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 2
  • Publication Date: 2017
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.320-324
  • Hacettepe University Affiliated: Yes


Purpose: HER2-amplified breast cancer (BC) has a poor prognosis. The combination of trastuzumab with chemotherapy in the adjuvant setting decreases recurrence and improves overall survival in HER2-positive BC. However, the role of adjuvant treatment in patients with HER2-amplified small BC without lymph node involvement is still under debate. The purpose of this study was to investigate the safety of adjuvant paclitaxel and trastuzumab (APT) in this group of patients.